Switch theme
Sign up to access all valuation multiples
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
2016
23
LTM Revenue $5.9M
LTM EBITDA n/a
$47.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Unicycive has a last 12-month revenue of $5.9M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Unicycive achieved revenue of n/a and an EBITDA of -$36.2M.
Unicycive expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Unicycive valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.7M | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$30.2M | -$36.2M | XXX | XXX | XXX |
| EBITDA Margin | -4471% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$18.1M | -$30.5M | XXX | XXX | XXX |
| Net Margin | -2675% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Unicycive's stock price is $1.
Unicycive has current market cap of $73.0M, and EV of $47.7M.
See Unicycive trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $47.7M | $73.0M | XXX | XXX | XXX | XXX | $-0.46 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Unicycive has market cap of $73.0M and EV of $47.7M.
Unicycive's trades at 8.1x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Unicycive's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Unicycive and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $47.7M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -1.3x | XXX | XXX | XXX |
| P/E | -2.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpUnicycive's NTM/LTM revenue growth is 1873%
Unicycive's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.4M for the same period.
Over next 12 months, Unicycive's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Unicycive's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Unicycive and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -100% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 20% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Unicycive acquired XXX companies to date.
Last acquisition by Unicycive was XXXXXXXX, XXXXX XXXXX XXXXXX . Unicycive acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Unicycive founded? | Unicycive was founded in 2016. |
| Where is Unicycive headquartered? | Unicycive is headquartered in United States of America. |
| How many employees does Unicycive have? | As of today, Unicycive has 23 employees. |
| Who is the CEO of Unicycive? | Unicycive's CEO is Dr. Shalabh Gupta, M.D.. |
| Is Unicycive publicy listed? | Yes, Unicycive is a public company listed on NAS. |
| What is the stock symbol of Unicycive? | Unicycive trades under UNCY ticker. |
| When did Unicycive go public? | Unicycive went public in 2021. |
| Who are competitors of Unicycive? | Similar companies to Unicycive include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Unicycive? | Unicycive's current market cap is $73.0M |
| What is the current revenue of Unicycive? | Unicycive's last 12-month revenue is $5.9M. |
| What is the current EV/Revenue multiple of Unicycive? | Current revenue multiple of Unicycive is 8.1x. |
| Is Unicycive profitable? | Yes, Unicycive is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
